Abstract
NO-sensitive guanylyl cyclase (NO-GC) acts as the receptor for nitric oxide and by the increase in cGMP executes most of the NO effects in the cardiovascular and neuronal system. Two isoforms of NO-GC exist whose existence has not been paid much attention to probably because they reveal comparable regulatory and catalytic properties and therefore cannot be differentiated in vivo. Analysis of mice in which either one of the isoforms has been genetically deleted unequivocally establishes the coexpression of NO-GC1 and NOGC2 in any tissue tested to date with the exception of platelets. In tissues other than brain and platelets, no particular function could be ascribed to a specific NO-GC isoform so far. In contrast, NO-GC1 and NO-GC2 serve different functions in the central nervous system. With NO-GC1's presynaptic role and NO-GC2's postsynaptic action, two NO/cGMP pathways have been shown to exist that enhance the strength of synaptic transmission on either side of the synaptic cleft.
Keywords: Nitric oxide, cGMP, guanylyl cyclase, knock-out, smooth muscle tone, blood pressure, inhibition of platelet aggregation, synaptic transmission.
Current Medicinal Chemistry
Title:Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Volume: 23 Issue: 24
Author(s): Doris Koesling, Evanthia Mergia and Michael Russwurm
Affiliation:
Keywords: Nitric oxide, cGMP, guanylyl cyclase, knock-out, smooth muscle tone, blood pressure, inhibition of platelet aggregation, synaptic transmission.
Abstract: NO-sensitive guanylyl cyclase (NO-GC) acts as the receptor for nitric oxide and by the increase in cGMP executes most of the NO effects in the cardiovascular and neuronal system. Two isoforms of NO-GC exist whose existence has not been paid much attention to probably because they reveal comparable regulatory and catalytic properties and therefore cannot be differentiated in vivo. Analysis of mice in which either one of the isoforms has been genetically deleted unequivocally establishes the coexpression of NO-GC1 and NOGC2 in any tissue tested to date with the exception of platelets. In tissues other than brain and platelets, no particular function could be ascribed to a specific NO-GC isoform so far. In contrast, NO-GC1 and NO-GC2 serve different functions in the central nervous system. With NO-GC1's presynaptic role and NO-GC2's postsynaptic action, two NO/cGMP pathways have been shown to exist that enhance the strength of synaptic transmission on either side of the synaptic cleft.
Export Options
About this article
Cite this article as:
Koesling Doris, Mergia Evanthia and Russwurm Michael, Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms, Current Medicinal Chemistry 2016; 23 (24) . https://dx.doi.org/10.2174/0929867323666160812145050
DOI https://dx.doi.org/10.2174/0929867323666160812145050 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Confocal Laser Scanning Microscope, Raman Microscopy and Western Blotting to Evaluate Inflammatory Response after Myocardial Infarction
Current Vascular Pharmacology Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology The Bid to Lose Weight: Impact of Social Media on Weight Perceptions, Weight Control and Diabetes
Current Diabetes Reviews MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges
Current Pharmaceutical Design Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism The Role of Direct Oral Anticoagulant in Patients with Acute Coronary Syndrome on Single or Dual Antiplatelet Regime: Review of Opportunities and Challenges
Current Reviews in Clinical and Experimental Pharmacology A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama
Current Aging Science Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology 3D Cell and Scaffold Patterning Strategies in Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Potential Therapeutic Applications of Metal Compounds Directed Towards Hypoxic Tissues
Current Medicinal Chemistry Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design